Latest News About Daraxonrasib Kras Protein Target

Latest news: Daraxonrasib (a KRAS-targeting drug; also referred to as RMC-6236) is generating attention for early clinical results in pancreatic cancer and for regulatory momentum.

What’s new recently

• Phase 1/2 pancreatic cancer results (May 2026 coverage): Multiple outlets report that daraxonrasib showed initial anti-tumor activity and the potential to improve outcomes versus current standard approaches in RAS-mutant pancreatic cancer, based on results led by researchers at UT MD Anderson Cancer Center.[4][6]
• Mechanism/targeting details (May 2026 coverage): Reports describe daraxonrasib as a “RAS(ON)” type approach that acts by forming a tri-complex involving KRAS and the chaperone protein CypA, with activity spanning multiple KRAS mutations (e.g., G12D, G12V, G12R, Q61X).[2]
• Broader KRAS-family angle (Apr 2026 coverage): Some writeups emphasize that daraxonrasib is designed to target KRAS and related RAS proteins, aiming to address limitations seen with earlier KRAS inhibitors that benefited only a small fraction of pancreatic cancer patients.[1]

Related prior context (helpful if you’re tracking the drug)

• FDA Breakthrough Therapy designation (late June 2025, still often referenced): FDA granted Breakthrough Therapy Designation to daraxonrasib for certain patients with metastatic PDAC harboring KRAS G12X mutations (as described in clinical/regulatory coverage).[7]

If you tell me which cancer type you care about most (pancreatic vs lung/colorectal/other) and whether you want only regulatory updates or only trial results, I can narrow the “latest news” to exactly that.